South Korea-based GC Cell has taken a monumental step in advancing cancer treatment on a global scale by partnering with Indonesia’s PT Bifarma Adiluhung (Bifarma) through a ‘Technology Transfer and License Agreement.’ Finalized after three months of collaboration, this agreement grants Bifarma exclusive rights to develop, produce, and market Immuncell-LC, South Korea’s pioneering anticancer drug cell therapy, for the next 15 years in Indonesia.
This partnership marks a significant leap for Bifarma, which operates the first GMP-certified cell therapy production facility in Indonesia. With its extensive sales and marketing infrastructure and a sophisticated cold chain distribution network, Bifarma is well-positioned to drive the success of Immuncell-LC throughout Indonesia.
James Park, CEO of GC Cell, expressed optimism about the collaboration, stating, “This agreement not only allows us to introduce Immuncell-LC to Indonesia by next year but also paves the way for future global expansion. Our joint effort with Bifarma will bring new cancer treatment options to patients in need.”
Immuncell-LC is expected to be a breakthrough in Indonesia’s oncology market, particularly for Hepatocellular Carcinoma (HCC), which affects thousands annually. As Indonesia’s pharmaceutical market grows rapidly, this partnership is poised to deliver a new wave of innovative treatments, enhancing the country’s cancer care capabilities.